Azora Therapeutics, Inc. (AZR) Price Prediction & ForecastAZRAzora Therapeutics, Inc.

Skyline Builders Group Holding Ltd (KAZR) is not a good buy right now due to its significant recent decline and negative financial indicators. The stock has dropped 22.70% over the last 5 days and 61.82% year-to-date, indicating a strong downtrend. Additionally, the current price of 1.26 is well below its 52-week high of 3.39, reflecting a lack of investor confidence. The RSI is at 37.63, suggesting the stock is oversold, but this could indicate a continued downtrend rather than an immediate buying opportunity. The termination of the merger agreement with Cove Kaz on November 2, 2026, adds to the uncertainty surrounding the company's future prospects. The main risk is the high volatility and the potential for further declines, as evidenced by the stock's 5-day change of -22.70%.

Azora Therapeutics, Inc. (AZR) last closed at $4, gaining +7.82%. These facts feed the 1-day and 1-week AZR price prediction above.